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Abbreviations 
AANA acetyl-alanine p-nitroanilide 
APEH acylpeptide hydrolase 
AUC area under the plasma concentration-time curve 
BNPP bis-p-nitrophenylphosphate 
BSA bovine serum albumin 
Cmax the maximal plasma concentration 
CYP cytochrome P450 
DDI drug-drug interaction 
DFP diisopropyl fluorophosphate 
DPD dihydropyrimidine dehydrogenase 
DRPM doripenem 
DTNB 5,5’-dithiobis(2-nitrobenzoic acid) 
EDTA ethylene diamine tetraacetic acid 
5-FU 5-fluorouracil 
IC50 half maximal inhibitory concentration 
IPI International Protein Index 
IS internal standard 
Km kinetic constant 
LC/MS/MS liquid chromatography-tandem mass spectrometry 
LDH lactate dehydrogenase 
MEPM meropenem 
P450 cytochrome P450 
PAPM panipenem 
PCMB p-chloromercuribenzoic acid 
PMSF phenylmethylsulfonyl fluoride 
pNPG p-nitrophenyl β-glucuronide 
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
t1/2 terminal half-life 
UDPGA uridine 5'-diphosphoglucuronic acid 
UGT uridine 5'-diphospho-glucuronosyltransferase 
VPA valproic acid 
VPA-G valproic acid glucuronide 
Vmax maximum velocity 
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General Introduction 
Drug-drug interactions (DDIs) occur when one therapeutic agent either alters the concentration 
(pharmacokinetic interactions) or the biological effect of another agent (pharmacodynamic interactions) [1].  
Pharmacokinetic DDIs can occur in processes of absorption, distribution, or clearance of the affected agent.  
Most clinical DDIs are relevant to metabolism, one of the clearance processes.  In the metabolic process, 
adding a polar group or unmasking is mediated by drug-metabolizing enzymes to increase hydrophilicity 
of drugs for efficient elimination from the body.  Although the majority of metabolism-mediated DDIs is 
related to inhibition or induction of cytochrome P450 (P450, CYP), one of the major drug-metabolizing 
enzyme clusters, there are a few cases of non P450 enzyme-related DDIs [2-4].  Of all, there was an 
unforgettable DDI mediated by dihydropyrimidine dehydrogenase (DPD), a non P450 enzyme [3].  DPD 
metabolizes 5-fluorouracil (5-FU), potent cancer chemotherapy drug.  In Japan, it was found that 
concomitant use with sorivudine led to significant accumulation of 5-FU due to the inhibition of DPD by 
bromovinyluracil, a metabolite of sorivudine, followed by severe bone marrow depression and death.  
Later, sorivudine was withdrawn despite the effectiveness of its 20- to 100-fold lower dose for herpes 
zoster than acyclovir [5]. 
DDI potential of investigational drugs is evaluated using in vitro human samples and in vivo 
testing in animal species before clinical studies [6].  However, sometimes the prediction fails because in 
vitro findings do not always reflect the complexities of the whole human body and there are interspecies 
differences between human and animal in vivo systems.  To overcome the problems, several research 
groups have developed chimeric mice, in which mouse liver is replaced by transplanted human liver cells 
[7-9].  Hasegawa et al. [7] have developed TK-NOG mice with humanized livers, which can sustain a 
high level of human engraftment over 8 months without special treatment other than a pathogen-free 
environment.  The humanized liver in the chimeric mice expressed mRNAs encoding many human P450 
enzymes, two uridine 5'-diphospho-glucuronosyltransferases (UGT), several transporters and transcription 
factors affecting drug metabolism at comparable levels to donor human hepatocytes, and exhibited the 
activity of CYP2D6, one of the major P450 enzymes involved in drug metabolism.  In addition, the utility 
of this animal model to predict human drug metabolism and DDIs related to CYP3A has been suggested 
[10, 11].  Thus, TK-NOG chimeric mice with humanized livers appear to be a functional tool to predict 
clinical DDIs, at least mediated by P450 enzymes, as well as clarify the mechanisms of clinical DDIs. 
Valproic acid (VPA), a simple, branched-chain fatty acid with a broad spectrum of anticonvulsant 
activity, is extensively used for treatment of various seizure types of epilepsy [12, 13].  Due to the 
versatility, VPA is often applied in combination with other antiepileptic agents [14].  Numerous types of 
DDIs between VPA and concomitantly used drugs including antiepileptic drugs have been reported [13], 
e.g., reduction in the plasma concentration of VPA by phenytoin or phenobarbital due to induction of 
hepatic drug-metabolizing enzymes [15]; enhanced VPA hepatotoxicity by phenytoin or carbamazepine 
due to the enhanced formation of 4-ene-VPA, a minor but toxic metabolite of VPA [16]; and inhibition of 
plasma protein binding of VPA by salicylic acid [15].   
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A clinically interesting DDI of VPA with carbapenem antibiotics has been reported [17, 18].  
Carbapenem antibiotics have a broad spectrum of antibacterial activity both against Gram-positive and 
Gram-negative bacteria, and are used frequently in treating various infections [13, 19, 20].  While patients 
are receiving carbapenems, the plasma levels of VPA decrease below the narrow therapeutic window 
(50 – 100 µg/mL), resulting in the recurrence of epileptic seizures [17, 18].  In 1996, the contraindication 
for co-administration of these drugs was added to the Information on Adverse Reactions to Drugs from the 
Ministry of Health, Labour and Welfare in Japan, whereas in other countries a careful concomitant use is 
allowed and clinical interactions have still been reported [21-25]. 
The mechanism of this pharmacokinetic interaction has been studied by a number of researchers 
[26].  Some mechanisms related to absorption, distribution and metabolism of VPA have been proposed 
[13, 27-30].  Among them, metabolism in the liver has been considered to be the most important for 
interaction, as based on the following findings.  VPA is mainly metabolized to the acylglucuronide 
(VPA-G) in the liver and subsequently excreted into bile and urine in rats.  In hepatectomized rats, the 
interaction of VPA with carbapenems was not observed [13].  After treatment with panipenem (PAPM) to 
rats, the biliary excretion of VPA-G increased and the biliary excretion clearance did not change, 
suggesting that the formation of VPA-G was apparently accelerated.  Although UGTs were not induced or 
activated by PAPM in rat liver microsomes, uridine 5'-diphosphoglucuronic acid (UDPGA) level was 
increased by 1.7 times, consistent with 1.8 times the increase of the apparent glucuronidation clearance of 
VPA [31].  However, VPA-G formation in monkey liver slice was increased 10 to 20 times by doripenem 
(DRPM), while the UDPGA level in the slice was increased only 1.4 times [29], suggesting that other 
processes contribute to the apparent acceleration in VPA-G formation.  As one of the interaction 
processes, it is considered that the inhibition of the hydrolysis of VPA-G to VPA apparently accelerates the 
VPA-G formation.  The hydrolysis of VPA-G was observed in rat and monkey liver homogenates [29].  
The hydrolysis in rat liver cytosol was strongly inhibited by DRPM [29].  After intravenous 
administration of VPA-G to rats, the exposure of VPA in plasma was decreased by carbapenems, 
demonstrating that VPA-G hydrolysis and the inhibition by carbapenems also occur in vivo [29].  
Collectively, VPA-G hydrolysis in the liver seems to be one of key processes for the interaction of VPA 
with carbapenems. 
This thesis aims to clarify the mechanism of this interaction based on the hypothesis that the 
inhibition of reverse hydrolysis to VPA from VPA-G by carbapenems causes the rapid decrease in plasma 
VPA levels.  In Chapter 1, a reverse hydrolase of VPA-G to VPA was successfully purified from human 
liver cytosol, where the VPA-G hydrolase activity is highly distributed.  This enzyme was identified as 
APEH, and further in vitro studies revealed that APEH, but not β-glucuronidase, is exclusively involved in 
PAPM-sensitive VPA-G hydrolysis in human liver.  APEH was considered to play a major role in this 
drug interaction via VPA-G hydrolysis. 
Chapter 2 focuses on in vivo DDI evaluation after co-administration of VPA with MEPM to dogs 
and chimeric mice with humanized livers.  In Section I, drug disposition and APEH activity after 
co-administration of VPA with MEPM to dogs were examined.  More rapid decrease in plasma VPA 
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levels after administration with MEPM revealed that the drug interaction in dogs occurs in a similar 
manner to humans.  In vitro characterization studies revealed that dog liver and kidney VPA-G hydrolase 
sensitive to carbapenems is cytosolic APEH, which is the same as in human liver.  Increased urinary 
excretion of VPA-G and negligible hepatic and renal APEH activity at 24 h after dosing of MEPM, 
indicated long-lasting inhibition of APEH-mediated VPA-G hydrolysis by MEPM in dogs.  Section II 
further examines the plausibility of the APEH-mediated DDI mechanism in TK-NOG chimeric mice with 
humanized livers, along with the capability of this animal model to evaluate DDI via non P450 enzyme. 
Chapter 3 describes the inhibition mechanism of APEH by carbapenems.  In vitro 
time-dependent inhibition and overnight dialysis studies revealed irreversible inhibition of APEH by 
carbapenems, consistent with the in vivo long-lasting inhibition of APEH after administration of MEPM in 
Chapter 2.  Decreased binding of MEPM to APEH pretreated with a serine hydrolase inhibitor, 
diisopropyl fluorophosphates (DFP), primarily explains the irreversible inhibition by selective binding to 
the active serine of APEH.  In this chapter, the chemical structure of carbapenems required for the 
inhibition was also examined by comparison with the open β-lactam ring form of MEPM and other classes 
of β-lactam antibiotics. 
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Chapter 1. Identification of VPA-G Hydrolase in Human Liver 
1. Introduction 
As the mechanism of interaction resulting in the decrease in plasma VPA level during concomitant 
use with carbapenems, the inhibition of reverse hydrolysis to VPA from VPA-G, the main metabolite of 
VPA has been suspected (Fig. 1-1).  Liver, the main metabolic organ for VPA, has been considered to be 
the most important for this interaction since the interaction was not observed in hepatectomized rats [13]. 
 
 
Figure 1-1.  Possible mechanism of drug interaction of VPA with carbapenems. 
 
In this chapter, the identification of VPA-G hydrolase from human liver cytosol, in which the 
hydrolase activity was highly located, is described.  Using antiserum, the contribution of the identified 
enzyme to VPA-G hydrolysis was determined. 
 
2. Results 
2.1 VPA-G Hydrolase Activity in Human Liver Subcellular Fraction and Inhibition by 
PAPM 
VPA-G hydrolase activity in human liver cytosol, microsomes, mitochondria and lysosomes at pH 
7.4 are shown in Fig. 1-2.  All the subcellular fractions showed hydrolase activity and cytosol had the 
highest activity.  Lysosomes also showed the VPA-G hydrolase activity at pH 5.  PAPM (0.03 mM) 
inhibited the VPA-G hydrolase activity in all the subcellular fractions, except for lysosomes at pH 5.  The 
subcellular distribution of lactate dehydrogenase (LDH) activity, a marker enzyme of cytosol, was almost 
consistent with that of the VPA-G hydrolase activity (Fig. 1-3). 
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Figure 1-2.  VPA-G hydrolase activity in human liver subcellular fractions.  Subcellular fractions 
without indication of pH were tested at pH 7.4.  Data represents the mean of duplicate determinations. 
 
 
Figure 1-3.  VPA-G hydrolase activity and LDH activity in human liver subcellular fractions at pH 
7.4.  Each activity is shown as % of cytosol.  Data represents the mean of duplicate determinations. 
 
2.2 VPA-G Hydrolysis by β-Glucuronidase 
Because VPA-G hydrolysis is a deconjugation of glucuronide, the author examined the possibility 
of the hydrolysis by β-glucuronidase in cytosol.  Saccharolactone, known as a β-glucuronidase inhibitor, 
decreased the hydrolytic activity in cytosol at pH 7.4 by 53.8% at 5 mM and abolished the activity at 25 
mM (Table 1-1).  However, commercially-available purified bovine liver β-glucuronidase hardly 
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hydrolyzed VPA-G at the same pH (0.710 pmol/Fishman unit/h).  Since β-glucuronidase is mainly located 
in lysosomes, the activity of this enzyme at lysosomal pH was also tested.  This enzyme showed greater 
activity at pH 5 (110 pmol/Fishman unit/h) than at pH 7.4.  However, the hydrolase activity at pH 5 was 
not inhibited by PAPM even at 0.3 mM, which is 10 times higher than the inhibitory concentration in 
cytosol at pH 7.4. (Table 1-2). 
 
Table 1-1.  Residual VPA-G hydrolase activity in human liver cytosol (HLC) and recombinant 
human APEH (rhAPEH) at pH 7.4 after treatment with various inhibitors.   
 
Data represents the mean of duplicate determinations.  N.D., not determined. 
 
Table 1-2.  Residual VPA-G hydrolase activity of purified bovine liver β-glucuronidase at pH 5 after 
treatment with inhibitors. 
 
Data represents the mean of duplicate determinations. 
 
2.3 Inhibition of VPA-G Hydrolase Activity by Typical Esterase Inhibitors VPA-G 
Hydrolysis by β-Glucuronidase 
 
Because VPA-G hydrolysis is a cleavage reaction of the carboxyl ester bond, the author examined 
Conc.
(mM) HLC rhAPEH
5 53.8 79.6
25 0 17.4
0.1 0 18.0
1 0 18.0
0.1 88.1 N.D.
1 102.5 N.D.
0.1 110.2 N.D.
1 85.6 N.D.
1 19.4 29.6
5 0 19.2
PCMB 1 0 19.5
1 108.9 N.D.
5 82.4 N.D.
Carbapenem-sensitive
VPA-G hydrolase
PAPM 0.03 14.0 23.1
Cholinesterase Eserine
Carboxylesterase BNPP
Esterase with SH-group
DTNB
Metalloenzyme EDTA
Typical target Inhibitors
Residual activity (%Control)
β-Glucuronidase
(APEH)
Saccharolactone
Serine esterase DFP
Conc. Residual activity
(mM) (%Control)
5 0
25 0
0.03 101.9
0.3 101.0
Inhibitors
Saccharolactone
PAPM
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the possibility of the hydrolysis by typical esterases in cytosol.  As shown in Table 1-1, DFP, a strong 
serine esterase inhibitor, completely inhibited the hydrolytic reaction at more than 0.1 mM.  Eserine and 
bis-p-nitrophenylphosphate (BNPP), a specific inhibitor for cholinesterase and carboxylesterase, showed 
little or no inhibition of the hydrolysis, respectively.  5,5’-Dithiobis(2-nitrobenzoic acid) (DTNB) and 
p-chloromercuribenzoic acid (PCMB), known as inhibitors of esterase containing SH-groups, completely 
inhibited the hydrolysis at 5 and 1 mM, respectively.  The inhibitory effect of ethylene diamine tetraacetic 
acid (EDTA), a chelate agent, was very weak. 
2.4 Purification of VPA-G Hydrolase from Human Liver Cytosol  
The author tried to purify VPA-G hydrolase(s) from human liver cytosol by anion exchange 
chromatography and hydroxyapatite affinity chromatography.  The active fractions were subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and a thick band was found at 75 
kDa (Fig. 1-4).  The 75-kDa protein band was digested with trypsin within the gel and the resulting 
peptides were extracted and sequenced by liquid chromatography-tandem mass spectrometry (LC/MS/MS).  
The MS/MS spectra data were searched against a composite target/decoy International Protein Index (IPI) 
human database using Mascot software.  As a result, the 75-kDa protein was identified as APEH (IPI 
accession number: IPI00337741) with a sequence coverage of 71% (Table 1-3).  
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Figure 1-4.  SDS-PAGE of VPA-G hydrolase purified from human liver cytosol.  Lane 1, molecular 
mass marker; lane 2, purified VPA-G hydrolase. The gel was revealed by silver staining.  
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Table 1-3.  Correspondence of tryptic peptides of a 75 kDa protein purified from human liver 
cytosol to human APEH (IPI accession number: IPI00337741). 
 
Sequence coverage is 71%.  
a 
Methionine in the peptides is identified as the oxidized form. 
Localization of peptide Mascot
in APEH sequence Score
ERQVLLSEPEEAAALYR 2-18 79
QVLLSEPEEAAALYR 4-18 71
QPALSAACLGPEVTTQYGGQYR 23-44 83
TVHTEWTQR 45-53 45
TVHTEWTQRDLER 45-57 20
QYLVFHDGDSVVFAGPAGNSVETR 66-89 114
GELLSRESPSGTMK 90-103 49
ESPSGTMKAVLR 96-107 54
KAGGTGPGEEKQFLEVWEK 108-126 32
QFLEVWEKNRK 119-129 45
KLKSFNLSALEK 129-140 49
LKSFNLSALEK 130-140 53
SFNLSALEK 132-140 53
HGPVYEDDCFGCLSWSHSETHLLYVAEK 141-168 87
AESFFQTKALDVSASDDEIAR 173-193 52
AESFFQTK 173-180 49
ALDVSASDDEIAR 181-193 83
LKKPDQAIKGDQFVFYEDWGENMVSK 194-219 87
LKKPDQAIK 194-202 40
GDQFVFYEDWGENMVSK 
a 203-219 99
RSALYYVDLIGGK 279-291 70
SALYYVDLIGGK 280-291 87
CELLSDDSLAVSSPR 292-306 118
IVYLQYPSLIPHHQCSQLCLYDWYTK 314-339 65
VTSVVVDVVPR 340-350 64
QLGENFSGIYCSLLPLGCWSADSQR 351-375 71
VVFDSAQR 376-383 55
SRQDLFAVDTQVGTVTSLTAGGSGGSWK 384-411 120
QDLFAVDTQVGTVTSLTAGGSGGSWK 386-411 143
LLTIDQDLMVAQFSTPSLPPTLK 
a
412-434 98
VGFLPSAGKEQSVLWVSLEEAEPIPDIHWGIR 435-466 77
VGFLPSAGK 435-443 48
EQSVLWVSLEEAEPIPDIHWGIR 444-466 85
VLQPPPEQENVQYAGLDFEAILLQPGSPPDK 467-497 51
TQVPMVVMPHGGPHSSFVTAWMLFPAMLCK 498-527 53
MGFAVLLVNYR 
a
528-538 77
GSTGFGQDSILSLPGNVGHQDVK 539-561 75
TPLLLMLGQEDR 
a
665-676 112
TPLLLMLGQEDRR 665-677 49
RVPFKQGMEYYR 677-688 29
STHALSEVEVESDSFMNAVLWLR 705-727 115
Peptide Sequence
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2.5 Inhibitory Effect of PAPM and Esterase Inhibitors on the VPA-G Hydrolytic Activity of 
Recombinant APEH 
The construct of human APEH (derived from IOH3679, Matching nucleotide accession number: 
NM_001640.3, Invitrogen) with FLAG tag was transfected in FreeStyle 293F cells and the resulting 
protein was purified using the affinity tag and two-step column chromatography.  Then, the inhibitory 
effect of PAPM and esterase inhibitors on the VPA-G hydrolytic activity of the recombinant human APEH 
was examined.  As shown in Table 1-1, PAPM significantly inhibited the hydrolase activity of the 
recombinant APEH at 0.03 mM.  The effect of DFP, DTNB, PCMB and saccharolactone on the 
recombinant APEH was similar to human liver cytosol as well. 
2.6 Immunodepletion of APEH by Rabbit Anti-human APEH Antiserum 
To examine the contribution ratio of APEH to VPA-G hydrolysis in human liver cytosol, rabbit 
anti-human APEH antibody was raised by multiple injections of recombinant human APEH.  The 
resultant antiserum showed a binding ability to APEH protein but it could not inhibit the APEH activity 
(data not shown), therefore, the author used an immunodepletion method.  Human liver cytosol was 
treated with the antiserum to deplete APEH.  Western blot analysis revealed that APEH was successfully 
depleted in the resulting cytosol (Fig. 1-5a).  The APEH depleted cytosol completely lacked the VPA-G 
hydrolase activity, whereas cytosol treated with preimmune serum kept 97% of the control activity (Fig. 
1-5b).  Similarly, acetyl-alanine p-nitroanilide (AANA), a typical substrate of APEH, was hardly 
hydrolyzed in APEH depleted cytosol (Fig. 1-5b).  In contrast, cytosolic β-glucuronidase activity, 
measured as p-nitrophenyl β-glucuronide (pNPG) activity, was not affected by depletion of APEH at pH 5 
(Fig. 1-5b).  Neither cytosol treated with anti-APEH antiserum, preimmune serum, nor buffer showed 
β-glucuronidase activity at pH 7.4. 
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Figure 1-5.  APEH depletion (a) and various hydrolytic activity (b) in human liver cytosol after 
treatment with preimmune serum and anti-human APEH antiserum.  Immunodepleted samples 
prepared in duplicate.  One sample each was subjected to Western blot analysis.  Hydrolytic activity is 
shown as the mean value or the value of the pooled sample.  The cytosol treated with buffer is shown as 
the control. 
3. Discussion 
First the localization of VPA-G hydrolase in the liver to determine a target fraction for the 
hydrolase identification was examined (Fig. 1-2).  The highest hydrolase activity was found in cytosol at 
neutral pH.  The VPA-G hydrolase activity at the same pH in the other fractions, such as microsomes, 
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mitochondria and lysosomes was considered to be contaminated fraction of cytosol since the activity of 
these fractions was almost in parallel with the activity of LDH, which is the marker enzyme for cytosol 
(Fig. 1-3).  Lysosomes also showed VPA-G hydrolase activity at acidic pH, which is optimal condition 
for lysosomal enzymes (Fig. 1-2).  An inhibition experiment by PAPM revealed that cytosolic VPA-G 
hydrolase activity at neutral pH is PAPM-sensitive, but lysosomal activity at acidic pH is insensitive.  
Thus, VPA-G hydrolase, subjected to inhibition by PAPM, is mainly located in cytosol. 
From human liver cytosol, a single enzyme with a molecular weight of 75 kDa as a VPA-G 
hydrolase was purified (Fig. 1-4).  This enzyme was identified as APEH, a serine peptidase.  The 
chemical inhibition profiles of the recombinant human APEH by PAPM and enzyme inhibitors (DFP, 
DTNB, PCMB and saccharolactone) was similar to that of human liver cytosol (Table 1-1).  Human liver 
cytosol from which APEH is removed by anti-APEH antiserum completely abolished the corresponding 75 
kDa-protein and VPA-G hydrolytic activity (Fig. 1-5).  These results demonstrate that APEH is a single 
enzyme involved in PAPM-sensitive VPA-G hydrolysis in human liver cytosol. 
The exclusive involvement of APEH to cytosolic VPA-G hydrolysis is also supported by the 
following findings.  Minor or no contribution of cholinesterase, carboxylesterase and metalloenzyme to 
cytosolic VPA-G hydrolysis is suggested by little or no effect on the VPA-G hydrolysis by either 
cholinesterase inhibitor (eserine), carboxylesterase inhibitor (BNPP) or metalloenzyme inhibitor (EDTA), 
as shown in Table 1-1.  Interestingly, involvement of β-glucuronidase in cytosolic VPA-G hydrolysis is 
considered to be negligible, since APEH depleted cytosol completely lacked VPA-G hydrolase activity 
without any loss of pNPG β-glucuronidase activity and purified bovine liver β-glucuronidase hardly 
hydrolyzed VPA-G at cytosolic pH (Table 1-3 and Fig. 1-5).  In contrast, Nakamura et al. [32] had 
concluded that VPA-G is hydrolyzed by β-glucuronidase other than serine esterase(s) in cytosol based on 
the inhibition profile that the VPA-G hydrolase activity was inhibited by saccharolactone, a 
β-glucuronidase inhibitor, but not by phenylmethylsulfonyl fluoride (PMSF), a serine esterase inhibitor.  
However, this profile is corresponding to that of APEH reported previously [33].  Thus, all the findings 
suggest the contribution of cytosolic APEH to the hydrolysis.  This is an example that hydrolase, but not 
β-glucuronidase, is the major enzyme which catalyzes the deconjugation of acylglucuronide. 
APEH (EC 3.4.19.1) is known as a cytosolic serine peptidase, which consists of four identical 
monomers with a molecular weight of 75 kDa.  It catalyzes the hydrolysis of N-acylated peptide to an 
acylamino acid and a peptide with a free N-terminus [34].  The physiological role of APEH is considered 
as a regulation of the turnover and function of proteins because it has been reported that the acylation of 
proteins is related to the stability, function and interaction with other proteins.  Other than N-acylated 
peptides, APEH also hydrolyzes simple esters such as p-nitrophenyl esters [35].  This is the first report to 
show the involvement of APEH in drug metabolism. 
APEH has been found in various tissues including the kidney, intestine and erythrocytes as well as 
the liver [36].  Therefore, the possibility cannot be ruled out that APEH in other tissues contributes to the 
interaction of VPA with carbapenems via VPA-G hydrolysis.  At least, renal APEH may contribute to the 
DDI since increase in urinary excretion of VPA-G was observed in rabbits after co-administration with 
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MEPM without significant change of the plasma VPA-G concentration-time profile [37].  VPA 
glucuronidation activity in the human liver and kidney microsomes is very similar [38] and the VPA-G 
hydrolase activities in both tissues are also comparable (data not shown).  As the total activity in the liver 
is considered to be greater than that in the kidney because of the difference of the blood flow and total 
protein between both tissues, hepatic APEH could play a major role for this DDI via VPA-G hydrolysis.   
4. Short Summary 
In summary, cytosolic APEH is a single PAPM-sensitive VPA-G hydrolase in human liver.  This 
work presents that APEH is involved in drug metabolism for the first time.   
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Chapter 2. Drug Disposition and APEH Activity after Administration of 
VPA with MEPM in Dogs and Chimeric Mice with Humanized Livers 
Chapter 2 focuses on in vivo DDI evaluation after co-administration of VPA with MEPM to dogs 
and chimeric mice with humanized livers.  This chapter consists of the following two sections.  Section I 
describes VPA and VPA-G dispositions after administration of VPA with MEPM to dogs.  Also in vitro 
characterization of dog VPA-G hydrolase, which is identified as the dog counterpart of APEH, and ex vivo 
APEH activity in dog biopsy samples after administration of MEPM were examined.  Section II describes 
in vivo DDI studies in chimeric mice with humanized livers and the utility of this animal model for 
evaluation of non P450-related DDI is discussed. 
I. VPA and VPA-G Disposition and APEH Activity after Administration of VPA with 
MEPM in Dogs and In vitro Studies to Identify Dog VPA-G Hydrolase 
1. Introduction 
The inhibition of reverse hydrolysis to VPA from VPA-G by carbapenems is considered to play a 
key role for the DDI of VPA with carbapenems.  In Chapter 1, a reverse hydrolase of VPA-G to VPA was 
successfully purified from human liver cytosol, where the VPA-G hydrolase activity is highly distributed.  
This enzyme was identified as APEH, and further in vitro studies revealed that APEH, but not 
β-glucuronidase, is exclusively involved in PAPM-sensitive VPA-G hydrolysis in human liver. 
Section I intends to clarify the relevance of APEH-mediated VPA-G hydrolysis in vivo through 
determination of ex vivo APEH activity in dog biopsy samples, and the disposition of VPA and VPA-G 
after co-administration of VPA with MEPM.  In parallel, in vitro characterization of APEH as dog VPA-G 
hydrolase was carried out.   
2. Results 
2.1 VPA and VPA-G in Plasma, Urine, and Bile after Intravenous Administration of VPA 
and MEPM to Dogs  
After administration of VPA with MEPM, terminal half-life (t1/2) was shorter than that after dosing 
of VPA only (Fig. 2-1 and Table 2-1).  Plasma clearance of VPA increased after co-administration with 
MEPM.  Urinary excretion of VPA-G increased from 1 h after administration of VPA in the 
MEPM-treatment group and the total urinary excretion (0 – 6 h) was 1.5-fold higher than the control group 
(Table 2-2).  The plasma level and bile excretion of VPA-G showed no change (Fig. 2-1, Table 2-1 and 
Table 2-2).  VPA was negligible in the urine and bile after co-administration with or without MEPM.  
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Figure 2-1.  Plasma concentration-time profiles of VPA and VPA-G after intravenous 
administration of VPA (30 mg/kg) with or without MEPM (100 mg/kg) to three dogs.  Each value 
represents mean ± SD. 
 
Table 2-1.  Pharmacokinetic parameters after intravenous administration of VPA (30 mg/kg) with 
or without MEPM (100 mg/kg) to three dogs. 
 
Each value represents mean ± SD.  
Parameter
AUC0-6h (mg·h/ml) 127 ± 10 87.2 ± 4.2 199 ± 59 193 ± 41
t1/2 (h) 0.76 ± 0.03 0.33 ± 0.07 0.59 ± 0.08 0.7 ± 0.16
CL (ml/h/kg) 237 ± 17 344 ± 17 - -
Vss (ml) 262 ± 15 227 ± 33 - -
tmax (h) - - 1.0 ± 0.0 1.2 ± 0.3
Cmax (mg/ml) - - 86.1 ± 31.3 85.2 ± 17.4
VPA VPA-G
VPA + Saline VPA + MEPM VPA + Saline VPA + MEPM
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Table 2-2.  Urinary and biliary excretion of VPA-G after intravenous administration of VPA 
(30 mg/kg) with or without MEPM (100 mg/kg) to three dogs. 
 
Each value represents mean ± SD. 
2.2 Identification of a VPA-G Hydrolase in Dog Liver and Kidney  
To confirm the location of a VPA-G hydrolase, VPA-G hydrolase activity in dog liver and renal 
subcellular fraction was measured.  The highest VPA-G hydrolase activity was found in the cytosol at pH 
7.4 both in the liver and kidney (Fig. 2-2).  The activity was inhibited by PAPM and MEPM (Fig. 2-2).  
Although the hydrolase activity was observed in lysosomes at pH 5, it was not affected by the carbapenems 
(Fig. 2-2). 
The sensitivity of the VPA-G hydrolase in dog liver and renal cytosol to esterase inhibitors was 
examined.  The VPA-G hydrolase activity in both cytosolic fractions was completely inhibited by DFP 
(0.1 and 1 mM) and PCMB (1 mM) and was partially affected by DTNB (1 mM) and saccharolactone (5 
mM) (Fig. 2-3). 
To examine the contribution ratio of APEH to VPA-G hydrolysis, APEH-depleted dog liver and 
renal cytosol by an immunodepletion method using rabbit anti-APEH antiserum was prepared.  The 
APEH depleted cytosol completely lacked the VPA-G hydrolase activity, whereas the cytosol treated with 
preimmune serum showed almost the same activity as the control (Fig. 2-4).  Similarly, AANA, a typical 
substrate of APEH, was hardly hydrolyzed in the APEH depleted cytosol (Fig. 2-4).  In contrast, cytosolic 
β-glucuronidase activity, measured as pNPG activity, was not affected by depletion of APEH at pH 5 (Fig. 
2-4).  Either the cytosol treated with anti-APEH antiserum, preimmune serum, or buffer showed a 
negligible β-glucuronidase activity at pH 7.4.  
VPA + Saline
0-1 h 14.1 ± 2.5 8.4 ± 1.1
1-2 h 16.4 ± 1.8 5.3 ± 0.5
2-4 h 11.0 ± 5.5 5.9 ± 1.5
4-6 h 7.6 ± 6.9 0.7 ± 0.2
Total 49.1 ± 13.1 20.3 ± 1.7
VPA + MEPM
0-1 h 12.2 ± 9.9 9.5 ± 3.9
1-2 h 30.6 ± 10.4 10.9 ± 5.3
2-4 h 25.7 ± 3.3 4.5 ± 1.7
4-6 h 5.1 ± 3.6 1.2 ± 1.4
Total 73.6 ± 13.4 26.1 ± 7.9
Excretion ratio (%)
Urine Bile
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Figure 2-2.  VPA-G hydrolase activity in dog liver and renal subcellular fractions.  Data represents 
the mean of duplicate determinations.  Subcellular fractions without indication of pH were tested at pH 
7.4. 
 
 
Figure 2-3.  Residual VPA-G hydrolase activity in dog liver and renal cytosol at pH 7.4 after 
treatment with various inhibitors.  Data represents the mean of duplicate determinations.  Data from 
human liver cytosol was reported in Chapter 1.  
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Figure 2-4.  Various hydrolytic activity in dog liver and renal cytosol after treatment with buffer, 
preimmune serum and anti-human APEH antiserum.  Immunodepleted samples prepared in duplicate.  
Data is shown as the mean value. 
 
2.3 APEH Activity in Dog Liver and Kidney after Co-administration with MEPM  
APEH activity measured as AANA hydrolase activity in the liver and renal S9 prepared from 
biopsy samples after administration of VPA with MEPM to a dog was negligible (Fig. 2-5). 
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Figure 2-5.  APEH activity in dog liver and renal S9 after intravenous administration of VPA 
(30 mg/kg) with or without MEPM (100 mg/kg) to a dog.  S9 was prepared from biopsy samples 
obtained at 6 h and 24 h after the administration. 
3. Discussion 
Plasma concentrations of VPA after administration of VPA and MEPM to dogs decreased more 
rapidly than after administration of VPA only (Fig. 2-1 and Table 2-1), demonstrating that the drug 
interaction of VPA with MEPM was also observed in dogs.  Urinary/biliary excretion of VPA itself was 
negligible in both groups after co-administration with and without MEPM, whereas increased urinary 
excretion of VPA-G was observed after co-administration with MEPM (Table 2-2), suggesting that VPA-G 
hydrolysis was inhibited by MEPM in dogs.  Increased plasma clearance of VPA after co-administration 
with MEPM also suggests an interruption of VPA supply from VPA-G by MEPM. 
Dog APEH was identified to be a VPA-G hydrolase through the examination of the subcellular 
location and characterization using both inhibitors and anti-APEH antiserum.  The highest VPA-G 
hydrolase activity was found in cytosol from both the liver and kidney at neutral pH and was inhibited by 
PAPM and MEPM (Fig. 2-2).  The hydrolase activity was also found in lysosomes at acidic pH and was 
not changed by PAPM and MEPM (Fig. 2-2).  Thus, dog VPA-G hydrolase, subjected to inhibition by 
carbapenems, is mainly located in cytosol in both the liver and kidney.  The inhibition profile of the 
VPA-G hydrolase activity in both dog liver and renal cytosol (Fig. 2-3) was quite similar to that of human 
liver cytosol and recombinant human APEH in Chapter 1.  APEH-depleted dog liver and renal cytosol 
prepared by immunodepletion using anti-APEH antiserum completely lacked the VPA-G hydrolytic 
activity as well as AANA, a typical substrate of APEH (Fig. 2-4).  β-Glucuronidase activity (pNPG 
hydrolase activity) was not changed by the depletion of APEH (Fig. 2-4).  These results demonstrate that 
APEH is a single VPA-G hydrolase in dog liver and renal cytosol as well as in humans. 
APEH activity was negligible in dog liver and kidney samples after co-administration with MEPM 
and the lack of in vivo APEH activity was maintained until 24 h (Fig. 2-5).  This is the first observation of 
the inhibition of APEH activity by a carbapenem under the in vivo condition.  The long-lasting inhibition 
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of dog APEH was consistent with clinical findings that the plasma VPA level after discontinuation of a 
carbapenem remained low for several days [21-25].  These findings suggest that APEH activity is also 
sustainably inhibited by carbapenems in clinical settings, contributing to the rapid decrease of plasma VPA 
levels in the case of concomitant use of both drugs.  The inhibition of renal APEH and increased urinary 
excretion of VPA-G by MEPM suggested that renal inhibition of hydrolysis to VPA from VPA-G also 
caused the decrease of VPA supply to plasma after renal uptake of VPA-G.  Further studies to investigate 
the renal disposition of VPA and VPA-G are required to confirm the contribution of inhibition of renal 
APEH to decrease plasma VPA levels. 
4. Short summary 
In summary, the DDI of VPA with carbapenems in dogs is caused by long-lasting inhibition of 
VPA-G hydrolysis mediated by APEH, resulting in rapid decrease in plasma VPA levels and increase in 
urinary excretion of VPA-G, suggesting the clinical importance of APEH-mediated VPA-G hydrolysis in 
the DDI mechanism.  This work presents the inhibition of APEH activity by a carbapenem under the in 
vivo condition for the first time.  This work also suggests the utility of animal in vivo models combined 
with in vitro assays to identify involved enzyme(s) for better understanding of DDI mechanisms. 
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II. VPA and VPA-G Disposition and APEH Activity after Administration of VPA with 
MEPM in Chimeric Mice with Humanized Livers 
1. Introduction 
Chimeric mice carrying humanized livers have received increased attention as a tool to evaluate 
clinical feasibility of DDI [6, 10].  A TK-NOG mouse with humanized liver is one of the chimeric animal 
models and two researches showed the capability to predict clinical feasibility of P450-related DDI in the 
TK-NOG chimeric mice [10, 11]. 
Chapter 1 and Section I in this chapter revealed that APEH is dog and human VPA-G hydrolase, 
and long-lasting inhibition of APEH-mediated VPA-G hydrolysis causes the DDI of VPA with 
carbapenems in dogs.  In Section II, VPA and VPA-G disposition and APEH activity in TK-NOG 
chimeric mice with humanized livers were examined after co-administration with MEPM in order to 
determine the capability of this animal model for prediction of clinical DDIs mediated by a non-P450 
enzyme, and plausibility of the APEH-mediated DDI mechanism. 
2. Results 
2.1 VPA and VPA-G in Plasma and Urine after Intravenous Administration of VPA and 
MEPM to Chimeric Mice  
Plasma VPA and VPA-G concentration-time profiles and respective pharmacokinetic parameters 
after administration of VPA with or without MEPM to chimeric mice with humanized livers and normal 
TK-NOG mice are shown in Fig. 2-6 and Table 2-3.  After administration of VPA, t1/2 of plasma VPA 
concentration in chimeric mice was prolonged compared with normal mice.  After administration of VPA 
with MEPM to chimeric mice, plasma VPA decreased with shorter t1/2 than that after dosing of VPA only.  
Area under the plasma concentration-time curve (AUC) and urinary excretion of VPA-G in the 
MEPM-treatment chimeric mice were 2.7-fold and 1.4-fold higher than the control chimeric mice (Table 
2-3 and Table 2-4). 
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Figure 2-6.  Plasma concentration-time profiles of VPA and VPA-G after intravenous 
administration of VPA (30 mg/kg) with or without MEPM (125 mg/kg) to chimeric mice with 
humanized livers and TK-NOG mice.  Data is shown as mean ± SD (N=3-4) except for VPA + saline 
group of chimeric mice, shown as mean (N=2).  Data at 0.25 h after dosing in VPA + MEPM group of 
chimeric mice is shown as mean (N=2). 
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Table 2-3.  Pharmacokinetic parameters of VPA and VPA-G after intravenous administration of 
VPA (30 mg/kg) with or without MEPM (125 mg/kg) to chimeric mice with humanized livers and 
TK-NOG mice. 
 
Parameters are shown as mean ± SD (N=3).  *Parameter is from one animal because it cannot be 
calculated from other two animals.  †The group consisted of two animals.  ‡The group consisted of four 
animals. 
 
Table 2-4.  Urinary excretion of VPA-G for 0-24 h after intravenous administration of VPA (30 
mg/kg) with or without MEPM (125 mg/kg) to chimeric mice with humanized liver and TK-NOG 
mice. 
 
Data is shown as mean ± SD (N=3). 
2.2 APEH Activity in Humanized Liver and Mouse Kidney Homogenates after 
Co-administration with MEPM 
APEH activity measured as AANA hydrolase activity in humanized liver and mouse kidney 
homogenates collected at 24 h after co-administration with MEPM to chimeric mice was decreased by 
75.4% and 31.4% of control, respectively (Table. 2-5). 
  
Parameter
VPA
AUC0-4h (μg·h/mL) 61.2 ± 2.6 57.4 ± 7.3 82.9 ± 25.6
T1/2 (h) 0.35 ± 0.02 0.35 ± 0.09 0.4 ± 0.05
CL (mL/h/kg) 456 ± 17 494 ± 85 397 ± 114
Vss (mL/kg) 228 ± 34 241 ± 25 182 ± 69
VPA-G
AUC0-4h (μg·h/mL) 35.6 ± 8.5 57.0 ± 9.8 77.4 ± 27.4
T1/2 (h) 0.23 ± 0.01 0.69 ± 0.90
Tmax (h) 0.42 ± 0.14 0.33 ± 0.14 0.44 ± 0.13
Cmax (μg/mL) 51.7 ± 13.7 67.7 ± 17.5 80.8 ± 20.8
0.25
23.5
0.22
*
142.8
0.82
199
228
29.1
0.87
VPA + saline VPA + MEPM VPA + saline
†
VPA + MEPM
‡
Chimeric miceTK-NOG mice
Parameter
VPA + saline VPA + MEPM VPA + saline VPA + MEPM
Urinary excretion
(%dose)
21.6 ± 9.9 42.8 ± 22.4 40.2 ± 6.0 55.4 ± 30.0
TK-NOG mice Chimeric mice
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Table 2-5.  APEH activity in the liver and kidney homogenate at 24 h after intravenous 
administration of VPA (30 mg/kg) with or without MEPM (125 mg/kg) to chimeric mice with 
humanized livers and TK-NOG mice. 
 
*Data is shown as mean of two samples, which are a sample derived from one animal and a mixture of 
tissues from two animals (erroneously mixed). 
3. Discussion 
Human in vitro and dog in vitro/in vivo findings in Chapter 1 and Section I in this chapter strongly 
suggest that inhibition of APEH-mediated VPA-G hydrolysis by carbapenems causes rapid decrease in 
plasma VPA levels below the therapeutic window.  However, APEH inhibition in clinical settings was 
unclarified.  TK-NOG chimeric mice with humanized liver, which is subjected to transplantation of 
normal human hepatocytes to their liver injured by ganciclovir treatment, have received increased attention 
as a functional tool to expect clinical pharmacokinetics/toxicity in recent years [7, 39, 40].  In this section, 
in order to examine the capability of this animal model for prediction of non P450-related DDIs and 
plausibility of the APEH-mediated mechanism in the DDI of VPA with carbapenems, in vivo APEH 
activity as well as VPA and VPA-G dispositions after co-administration of VPA with MEPM to the 
chimeric mice were investigated. 
After co-administration with MEPM to the chimeric mice, t1/2 of plasma VPA was shorter than that 
after administration of VPA only (0.82 h and 0.35 h), suggesting that the DDI of VPA with MEPM occurs 
in chimeric mice in the same manner as in dogs and in clinical settings (Fig. 2-6 and Table 2-3).  The 
DDI could not occur in normal TK-NOG mice.  This is the first example showing the capability to 
evaluate a non P450-related DDI in chimeric mice.  
Terminal half-life of plasma VPA in the chimeric mice did not reach that of ca. 12 h in clinical 
settings.  This discrepancy is possibly explained by the interspecies difference in VPA glucuronidation 
activity.  VPA glucuronidation activity by UGT in mouse-derived tissues including survived mouse liver 
cells in humanized livers in the chimeric mice may be higher than that in human tissues.  Plasma t1/2 of 
VPA in mice, rats, dogs and cynomolgus monkeys is much shorter than the clinical parameter, (Table 2-3, 
Section I in this chapter) [13, 29].  Furthermore, VPA-G concentration in human plasma is very low 
compared with those animals (Fig. 2-6, Section I in this chapter) [13, 29, 41].  These findings suggest that 
the VPA-G formation rate in humans is small.  Although kinetic parameters of VPA-G formation in 
mouse and monkey liver microsomes are not available, VPA-G formation clearance determined using 
human liver microsomes is lower than that of rat, or dog liver microsomes [31, 38].  The interspecies 
difference in APEH activity may less impact the VPA clearance since APEH activity in rat, dog and human 
liver cytosol was comparable (Chapter 1, Section I in this chapter and unpublished data).  Hence, such an 
VPA + saline VPA + MEPM VPA + saline VPA + MEPM
Liver 9.26 ± 5.61 3.07 ± 0.37 17.0 ± 5.0 4.19 ± 0.98
Kidney 12.8 ± 3.4 10.7
* 12.5 ± 2.1 8.57 ± 1.25
Homogenate
APEH activity (nmol/min/mg)
TK-NOG mice Chimeric mice
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interspecies difference of metabolism between humanized liver and mouse cells may limit quantitative use, 
however, this animal model could be useful to examine qualitative clinical feasibility of a DDI and its 
mechanism. 
In the chimeric mice, decrease in APEH activity in the humanized liver and intact mouse kidney, 
and increase in AUC and urinary excretion of VPA-G were observed (Table 2-3, Table 2-4 and Table 2-5), 
indicating that inhibition of APEH-mediated VPA-G hydrolysis by carbapenems causes the DDI of VPA 
with carbapenems in the chimeric mice as well as in dogs (Section I in this chapter).  This is the first 
observation to suggest that human APEH activity is inhibited by MEPM in vivo.  While renal APEH 
activity was equal both in normal and chimeric mice and was weakly inhibited by MEPM, the DDI 
occurred only in chimeric mice.  These results indicate that hepatic APEH in humanized liver contributes 
to the longer t1/2 of plasma VPA level in the chimeric mice by more effective recycling of VPA from 
VPA-G compared to normal mice, suggesting the importance of hepatic APEH in the clinical DDI as well. 
The inhibition of APEH-mediated VPA-G hydrolysis by carbapenems is considered to be the most 
plausible mechanism for the interaction in humans and animals in common, based on the following 
findings.  The significant increase of VPA-G formation in rat, monkey and human liver materials in vitro 
after incubation of VPA with carbapenems and increased excretion of VPA-G in rats, dogs and chimeric 
mice with humanized livers in vivo after co-administration of VPA with carbapenems were observed 
(Chapter 1 and this chapter) [29, 42].  Neither induction nor activation of UGT by PAPM was observed in 
rat in vitro and in vivo examinations [31].  VPA-G hydrolysis to VPA after administration of VPA-G to 
rats was inhibited by co-administration with carbapenems [29].  APEH was identified to be dog and 
human VPA-G hydrolase sensitive to carbapenems, and in vivo inhibition of APEH activity by MEPM in 
dogs and chimeric mice with humanized livers was found along with increased excretion of VPA-G and 
the rapid decrease of plasma VPA levels in Chapter 1 and this chapter.  Collectively, the inhibition of 
APEH-mediated VPA-G hydrolysis is observed as the acceleration of VPA-G formation, resulting in the 
increased excretion of VPA-G and rapid decrease of VPA in plasma.  In contrast, the other 3 proposed 
mechanisms, namely, 1) interaction in the intestinal absorption process, 2) interaction in the enterohepatic 
circulation process, and 3) interaction in the blood cell distribution process [26], are less likely in humans 
than the interaction in the VPA-G hydrolysis process.  Torii et al. [28] reported that the maximal plasma 
concentration (Cmax) and AUC of VPA was decreased by 50 – 60% after oral administration of VPA with 
treatment of imipenem and PAPM to rats, suggesting that the intestinal absorption of VPA might be 
inhibited by carbapenems.  However, the plasma level of VPA was also decreased at later time points, 
even after intravenous administration of VPA with the carbapenems [28].  In a case report of a Chinese 
patient who received 800 mg of VPA (p.o., once daily), the plasma concentration of VPA was decreased 
from 39 µg/mL to 10 µg/mL after MEPM treatment (1 g, i.v., twice daily) and it was not improved by the 
change of the dose regimens of VPA (400 mg i.v. and 1200 mg p.o., once daily) and MEPM (0.5 g i.v., 
twice daily) [25].  These findings indicate that the interaction of VPA and carbapenems occur after 
intravenous administration of VPA as well as after the oral administration, and the inhibition of intestinal 
absorption of VPA would not be significant in rats and humans.  Kojima et al. [27] reported that the 
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decrease of VPA in plasma was not observed after intravenous administration of VPA and PAPM to bile 
duct-cannulated rats, suggesting that carbapenems excreted into bile may suppress the enterohepatic 
recirculation of VPA by killing intestinal flora, which deconjugates VPA-G in gut.  However, this result 
has been controversial because the other report showed that the interaction occurred in bile duct-cannulated 
rats [13].  In addition, the biliary concentrations of carbapenems in humans are less than that of other 
β-lactam antibiotics, which can also kill intestinal flora and have been reported not to interact with VPA 
[18, 43-47], supporting that the interaction in the enterohepatic circulation process would be improbable in 
humans.  As to the blood cell distribution process, Omoda et al. [30] reported that the blood levels of VPA 
were not changed when the plasma level was decreased after intravenous administration of VPA with 
carbapenems in rats.  However, both the blood and plasma levels of VPA were decreased in patients [30], 
therefore, this mechanism does not contribute to the interaction in humans.  Thus, the inhibition of 
VPA-G hydrolysis in the liver is the most plausible mechanism of the interaction of VPA with carbapenems 
in humans at present. 
4. Short summary 
In summary, this is the first example to show the capability of chimeric mice with humanized 
livers as a functional tool for evaluation of DDIs via non P450 enzymes.  In the same manner as in dogs, 
in chimeric mice with humanized livers, the DDI of VPA with carbapenems is caused by long-lasting 
inhibition of APEH-mediated VPA-G hydrolysis, resulting in a rapid decrease in plasma VPA level and 
increase in urinary excretion of VPA-G.  These results obtained in this chapter strongly support that this 
APEH inhibition is the most plausible mechanism for the clinical DDI of VPA with carbapenems and 
hepatic APEH is the major contributor to the DDI. 
  
  31 
Chapter 3. The Long-lasting Inhibition Mechanism of APEH by 
Carbapenems: In Vitro Studies using Human Liver Cytosol and 
Purified Porcine APEH with a Similar Property to Its Human 
Counterpart 
1. Introduction 
Chapter 3 describes the inhibition mechanism of APEH by carbapenems.  Chapter 2 reveals that 
long-lasting inhibition of VPA-G hydrolysis mediated by APEH causes the DDI of VPA with MEPM in 
dogs and chimeric mice with humanized liver.  In Chapter 3, the inhibition mechanism of APEH by 
carbapenems was investigated focusing on reversibility, the site of action on the enzyme and the important 
structure of carbapenems comparing to its open β-lactam ring form (Fig 3-1) and other class of β-lactam 
antibiotics.  Human liver cytosol and purified porcine APEH with a similar property to its human 
counterpart were used as APEH enzyme sources in this chapter. 
 
Figure 3-1.  Chemical structures of PAPM, MEPM and open β-lactam ring form of MEPM.   
* 
14
C-labeled position of 
14
C-MEPM used in Chapter 3. 4. 
2. Results 
2.1 Kinetic Parameters of VPA-G Hydrolytic Activity of APEH in Human Liver Cytosol and 
Purified Porcine Liver APEH 
Km and Vmax values of the VPA-G hydrolytic activity in human liver cytosol and purified porcine 
liver APEH were calculated to be 3.06 µM and 0.238 nmol/min/mg protein, and 7.83 µM and 253 
nmol/min/mg protein, respectively. 
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2.2 Preincubation Time-dependency of Inhibition of APEH by Carbapenems 
At a substrate concentration of 3 μM (approximately equal to Km), both PAPM and MEPM 
inhibited APEH in human liver cytosol without preincubation and half maximal inhibitory concentration 
(IC50) values were 1.77 and 3.50 μM, respectively.  The inhibitory effect was enhanced approximately 
20-fold after preincubation for 30 min (Table 3-1). 
 
Table 3-1.  Preincubation time-dependency of inhibitory effect of PAPM and MEPM on APEH in 
human liver cytosol. 
 
IC50 values were calculated from the mean of duplicate determinations at each test concentration. 
2.3 Effect of Dialysis on Interaction between Porcine APEH and MEPM 
Because of the comparable Km, the similar inhibition profiles by typical hydrolase inhibitors (data 
not shown) and 92% identity of amino acid sequence [48], purified porcine APEH was used in this 
experiment instead of the human counterpart.  Porcine APEH was dialyzed after incubation with or 
without MEPM and the VPA-G hydrolytic activity was measured.  Before dialysis, APEH activity 
incubated with MEPM decreased to 10.5% of that without MEPM.  After overnight dialysis, the activity 
of APEH incubated with MEPM was not recovered (6.2% of activity without MEPM treatment).  The 
remaining binding ratio of 
14
C-labeled MEPM to APEH after overnight dialysis was 61.2%, whereas the 
binding ratio of 
14
C-MEPM to bovine serum albumin (BSA) was 6.3% (Table 3-2).  After preincubation 
of APEH with DFP, the binding ratio of 
14
C-MEPM to APEH decreased to 12.1% (Table 3-2).  The 
binding ratio of 
14
C-MEPM to BSA did not change by DFP treatment (Table 3-2). 
 
  
Preincubation time IC50
(min) (μM)
0 1.77
10 0.231
30 0.0857
0 3.5
10 0.41
30 0.161
Carbapenem
PAPM
MEPM
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Table 3-2.  Inhibitory effect of DFP on the binding of MEPM to purified porcine APEH and BSA. 
 
Data represent the mean ± S.D. of triplicate determinations.  
2.4 Inhibitory Effect of Open β-Lactam Ring Form of MEPM and Other β-Lactam 
Antibiotics on APEH 
The open β-lactam ring form of MEPM did not show the inhibitory effect on APEH activity in 
human liver cytosol even at 100 μM.  Likewise, other β-lactam antibiotics, which have a different ring 
structure adjacent to the β-lactam ring compared with carbapenems and various lengths of the side chains, 
did not inhibit the APEH activity (Table 3-3). 
 
Table 3-3.  Inhibitory effect of β-lactam antibiotics on acylpeptide hydrolase in human liver cytosol. 
 
Data represent the mean of duplicate determinations.   
  
Binding ratio
(%)
- 61.2 ± 2.2
+ 12.1 ± 1.5
- 6.3 ± 0.7
+ 6.6 ± 0.4
Protein DFP
APEH
BSA
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3. Discussion 
The author examined the inhibition characteristics of VPA-G hydrolase activity of APEH by 
carbapenems, which would lead to a decrease in the plasma concentration of VPA.  PAPM and MEPM 
inhibited APEH in human liver cytosol with 1.70 and 3.50 μM of IC50, respectively.  These values are 
clinically relevant because the Cmax values of PAPM and MEPM in humans were around 70 – 160 μM 
[19].   
The inhibitory effect of the carbapenems on APEH was dependent on the preincubation time.  
After preincubation with carbapenems for 30 min, PAPM and MEPM showed smaller IC50 (0.0857 and 
0.161 μM, respectively, Table 3-1).  A similar preincubation time-dependency was also confirmed in the 
previous report [49].  Thus, carbapenems inhibit APEH irreversibly.  In addition, these observations are 
consistent with long-lasting inhibition of APEH in the dog and humanized chimeric mice in Chapter 2 and 
the delayed recovery of plasma VPA levels in clinical conditions [21-25].  In contrast, the open β-lactam 
ring form of MEPM did not affect APEH activity even at 100 μM, indicating that the inhibition of APEH 
by carbapenems requires the closed β-lactam ring structure. 
To further characterize the irreversible inhibition mechanism, the dialytic effect on APEH after 
incubation with MEPM was examined.  The activity of purified porcine APEH decreased by 89.5% and it 
did not recover after overnight dialysis (93.8% inhibition), also demonstrating that the inhibition was 
irreversible.  The binding ratio of MEPM to APEH after dialysis was 61.2% (Table 3-2), suggesting that 
the inhibition of APEH by MEPM is primarily explained by strong binding of MEPM to the enzyme.  The 
difference between the inhibitory effect of APEH activity by MEPM (93.8%) and the binding ratio (61.2%) 
after dialysis is unclarified.  However, the structural modification in the active site of some APEH 
enzyme molecules might occur when leaving MEPM fragment, resulting in enzyme inactivation, as seen in 
the inhibition mechanism of class A serine β-lactamase by clavulanic acid [50].  By preincubation of 
APEH with DFP, the binding ratio of MEPM to APEH decreased to 12.1%.  DFP is known to inhibit 
serine hydrolases such as APEH by covalently binding to the active serine of enzymes [51].  Thus, the 
irreversible inhibition mechanism of carbapenems would be primarily explained by binding to the active 
serine of APEH.  In addition, low binding ratio of MEPM to BSA was not changed by DFP (Table 3-2), 
suggesting that the binding of MEPM to APEH is selective. 
Despite the binding selectivity to APEH, a little portion of MEPM also bound to BSA.  It might 
have been caused by the high reactivity of the β-lactam ring of carbapenems.  After administration of 
biapenem to rats, an amide metabolite with the open β-lactam ring structure was observed in plasma and 
urine [52].  This metabolite seems to be produced by a nonenzymatic nucleophilic attack to the carbonyl 
carbon of the closed β-lactam ring by the amino group of cystine, since mixing biapenem with amino acid 
infusions containing cystine (and also cysteine) leads to the degradation of biapenem, as stated in the 
Japanese package insert of biapenem.  As for thienamycin (the primary carbapenem) and MEPM, a 
similar reaction with cysteine has been reported [53, 54].  Thus, the β-lactam ring of carbapenems could 
have some reactivity to proteins. 
The proposed irreversible inhibition mechanism of APEH by carbapenems, that is, the binding to 
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the active serine of APEH, resembles that of antibacterial activity.  The β-lactam ring attacks the active 
serine in penicillin binding proteins, which is needed for the last step of cell wall production in bacteria, 
resulting in the formation of a stable ester bond with the open β-lactam ring structure [55, 56].  Although 
this pharmacological function is considered to be common among all the β-lactam antibiotics such as 
penicillins and cephems, they have not been reported to interact with VPA.  This may be caused by the 
following structural differences: 1) the heterocyclic structure adjacent to β-lactam ring, 2) the length of 
side chain attached to β-lactam ring, 3) the relative configuration of the side chain.  Unique 
five-membered non-heterocycle ring structure and/or relative configuration of the side chain of 
carbapenem structure could contribute to the inhibition potential because clavulanic acid and three 
penicillins did not inhibit APEH (Table 3-3).  The small side chain attached to carbapenem β-lactam ring 
was considered to enable the β-lactam ring to readily attack the active serine of APEH.  However, no 
inhibition by clavulanic acid with no side chain and 6-aminopenicillanic acid with an amino group 
suggests that the small side chain is unrelated to the APEH inhibition. 
Regarding the binding of carbapenems to the active serine of APEH, the author cannot rule out the 
possibility that carbapenems inhibit other serine esterases involved in drug metabolism, such as 
carboxylesterase and cholinesterase.  However, there are no articles reporting the interactions between 
carbapenems and ester drugs hydrolyzed by those esterases (such as angiotensin converting enzyme 
inhibitors) thus far.  Therefore, carbapenems are unlikely to affect other serine esterase activities in 
clinical practice. 
4. Short summary 
In summary, carbapenems irreversibly inhibit APEH.  To exert the inhibitory effect, the closed 
β-lactam ring structure is essential and other unique structures of carbapenems would contribute to the 
inhibition.  The inhibition mechanism is primarily explained by selective binding to the active serine of 
APEH. 
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Summary 
This thesis has investigated the mechanism of the DDI between VPA and carbapenems, based on 
the hypothesis that the inhibition of reverse hydrolysis to VPA from VPA-G by carbapenems causes the 
rapid decrease in plasma VPA levels.  The author identified VPA-G hydrolase as APEH, and examined in 
vivo inhibition of this hydrolase by carbapenems in dogs and chimeric mice with humanized livers, and the 
mechanism of inhibition using in vitro biological sources.  New findings provided from the present 
research are described in the following. 
Chapter 1 describes the identification of VPA-G hydrolase in human liver, which is considered to 
be a key molecule to maintain plasma VPA levels via VPA-G hydrolysis.  The highest VPA-G hydrolase 
activity was found in human liver cytosol at neutral pH.  The cytosolic VPA-G hydrolase was inhibited by 
DFP and PAPM, but not BNPP and eserine, suggesting that PAPM-sensitive VPA-G hydrolase in cytosol 
was serine hydrolase, but not well-known serine esterases, namely, carboxylesterase and cholinesterase.  
Through successive column chromatography, the cytosolic VPA-G hydrolase was identified as APEH, 
serine peptidase.  This is the first study to find an involvement of APEH in drug metabolism.  The 
chemical inhibition profile of recombinant human APEH by enzyme inhibitors was quite similar to that of 
cytosolic VPA-G hydrolase.  APEH-depleted cytosol, prepared by an immunodepletion method using 
anti-APEH serum, completely abolished the activity to hydrolyze VPA-G and the typical substrate of 
APEH.  Lysosomal and cytosolic β-glucuronidase is unrelated to PAPM-sensitive VPA-G hydrolysis.  
These findings indicate that cytosolic APEH exclusively catalyzes PAPM-sensitive VPA-G hydrolysis in 
human liver.  These findings also provide an example that hydrolase, but not β-glucuronidase, is a major 
enzyme which catalyzes the deconjugation of acylglucuronide. 
Chapter 2 describes the examination of the inhibition of APEH-mediated VPA-G hydrolysis and 
the resulting change in the dispositions of VPA and VPA-G after co-administration of VPA with MEPM in 
animals.  In Section I, an examination of the drug disposition and APEH activity in dog in vivo, along 
with identification of dog VPA-G hydrolase, was carried out.  A more rapid decrease in plasma VPA 
levels after co-administration with MEPM revealed that the drug interaction in dogs occurs in the same 
manner as clinical settings.  Increased urinary excretion of VPA-G and plasma clearance of VPA after 
co-administration with MEPM suggest that inhibition of VPA-G hydrolysis by MEPM causes an 
interruption of the VPA supply into plasma from VPA-G hydrolysis, resulting in accelerated urinary 
excretion of VPA-G.  The accelerated urinary excretion of VPA-G also suggests the involvement of a 
renal enzyme in VPA-G hydrolysis.  Dog VPA-G hydrolase in the liver and kidney was identified as 
cytosolic APEH through the examination of the subcellular location and characterization using both 
inhibitors and anti-APEH antiserum.  The highest dog VPA-G hydrolase activity was found in cytosol 
from the liver and kidney.  The inhibition profile of the cytosolic VPA-G hydrolase activity in the dog 
liver and kidney by chemical inhibitors including PAPM and MEPM was quite similar to that of the human 
liver cytosol and recombinant human APEH in Chapter 1.  APEH-depleted dog liver and renal cytosol 
prepared by immunodepletion using anti-APEH antiserum completely abolished the VPA-G hydrolytic 
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activity as well as a typical substrate of APEH.  These results demonstrate that cytosolic APEH is a major 
VPA-G hydrolase in dog liver and kidney as well as in human liver.  It is noteworthy that ex vivo APEH 
activity was negligible in dog liver and kidney samples obtained after co-administration with MEPM, and 
the lack of APEH activity was maintained until 24 h, consistent with a sustainable low level of plasma VPA 
for several days even after discontinuation of carbapenem in clinical settings.  These findings suggest that 
the DDI of VPA with carbapenems in dogs is caused by the long-lasting inhibition of VPA-G hydrolysis 
mediated by APEH, resulting in the rapid decrease in plasma VPA levels and an increase in urinary 
excretion of VPA-G.  Furthermore, this study suggests the utility of animal in vivo models combined with 
in vitro examinations to identify the involved enzymes for a better understanding of clinical DDI 
mechanisms. 
Section II describes the drug disposition and APEH activity in chimeric mice with humanized 
livers after co-administration of VPA with MEPM.  Similar to the findings in dogs in Section I, chimeric 
mice with humanized livers showed rapid decrease in plasma VPA, increased urinary excretion of VPA-G 
and long-lasting inhibition of APEH in humanized liver after co-administration, suggesting the clinical 
importance of APEH-mediated VPA-G hydrolysis in the DDI mechanism.  In addition, hepatic APEH was 
a major contributor to the DDI since normal mice with intact livers did not show the DDI.  Although the 
plasma t1/2 of VPA did not reach that in the clinical setting, chimeric mice with humanized livers are 
suggested to be a functional tool for assessing the qualitative clinical feasibility of DDIs via a non-P450 
enzyme, and for clarifying DDI mechanisms. 
Chapter 3 addresses the inhibition mechanism of APEH by carbapenems.  Preincubation 
time-dependent inhibition of VPA-G hydrolysis in human liver cytosol with carbapenems suggests 
irreversible inhibition of APEH by carbapenems.  Purified porcine liver APEH, which showed 
comparable Km, the similar chemical inhibition profiles and 92% identity of amino acid sequence with its 
human counterpart, lacked VPA-G hydrolase activity after incubation with MEPM, and the lacking activity 
did not recover after overnight dialysis.  These observations are consistent with long-lasting inhibition of 
APEH in dogs and chimeric mice with humanized livers, and the delayed recovery of plasma VPA levels in 
clinical settings.  The irreversible inhibition is primarily explained by the selective binding to the active 
serine of APEH since preincubation of porcine APEH with DFP, which binds to the active serine of serine 
proteases, prevented the binding of MEPM to APEH.  The open β-lactam ring form of MEPM, clavulanic 
acid and three penicillins with various sizes of side chains attached to β-lactam ring lacked the inhibitory 
effect upon VPA-G hydrolysis in human liver cytosol, suggesting that the closed β-lactam ring is essential, 
and other structural properties unique to carbapenems, such as its non-heterocyclic structure and relative 
configuration of the side chain of the β-lactam ring, may affect the inhibition. 
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Concluding Remarks 
This thesis investigated the DDI mechanism of VPA with carbapenems based on the hypothesis 
that the inhibition of reverse hydrolysis to VPA from VPA-G by carbapenems causes the rapid decrease in 
plasma VPA levels.  The important findings of the present work are listed as concluding remarks of this 
thesis: 
1). Cytosolic APEH is a single PAPM-sensitive VPA-G hydrolase in human liver.  The involvement of 
APEH in drug metabolism was shown for the first time.  The present work also provides an example 
that hydrolase is a major enzyme in the catalyzation of the deconjugation of acylglucuronide, which is 
primarily considered to be mediated by β-glucuronidase. 
2). The clinical importance of APEH-mediated VPA-G hydrolysis in the DDI mechanism is suggested 
through dog in vitro/in vivo and chimeric mice with humanized liver in vivo examinations.  Utility of 
the animal model used in this work is also suggested. 
 Long-lasting inhibition of APEH-mediated VPA-G hydrolysis by MEPM caused the DDI of VPA 
with MEPM in dogs and chimeric mice with humanized livers, resulting in the rapid decrease in 
plasma VPA levels and increase in urinary excretion of VPA-G.  In vivo inhibition of APEH 
activity after administration of carbapenem was shown for the first time.   
 Hepatic APEH was a major contributor to the DDI and renal APEH might be involved in part. 
 This work is the first example to show the capability of chimeric mice with humanized livers to 
evaluate DDIs via a non-P450 enzyme. 
3). Carbapenems irreversibly inhibit APEH.  The inhibition mechanism is primarily explained by 
selective binding to the active serine of APEH.  The closed β-lactam ring in the carbapenem 
structure is essential for the inhibition. 
Finally, this research will contribute to bringing much attention to safer clinical use of VPA and 
carbapenems (whose concomitant use is still allowed in the world, except for Japan), through better 
understanding the DDI mechanism of both drugs.  Furthermore, the present work would give us novel 
scientific knowledge that the inhibition of reverse metabolism could be a cause of the drug interaction, 
especially in the case that the relevant reverse pathway is converted from a main metabolite to the parent 
drug mediated by a single enzyme.  Moreover, the methodologies used in this research, combination of 
animal in vivo model with in vitro examinations including the identification of the responsible enzyme for 
reverse metabolism, would be widely applicable for future research of reverse metabolism-related DDIs.  
Thus, the author hopes that these findings will aid in the understanding of unclarified mechanisms of DDI 
in the future. 
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Experimental 
Chapter 1 
1. Materials 
VPA-G was synthesized enzymatically in Chemtech Labs, Inc. (Tokyo, Japan).  PAPM was 
synthesized in Sankyo Co., Ltd. (Tokyo, Japan).  VPA sodium salt and EDTA were purchased from Sigma 
Chemical Co. (St. Louis, MO).  DFP, eserine, p-nitroaniline, pNPG and p-nitrophenol were purchased 
from Wako Pure Chemicals (Osaka, Japan).  BNPP and DTNB were purchased from Nacalai Tesque, Inc. 
(Kyoto, Japan).  PCMB and saccharolactone were purchased from Research Organics (Cleveland, OH) 
and MP Biomedicals, Inc. (Solon, OH), respectively.  AANA was purchased from Bachem AG 
(Bubendorf, Switzerland).  The other reagents were all commercially available and of guaranteed grade.  
Pooled human liver subcellular fractions and human liver tissue used for the purification of VPA-G 
hydrolase were obtained from XenoTech, LLC. (Lenexa, KS) and Human & Animal Bridging Research 
Organization (Chiba, Japan).  Bovine liver β-glucuronidase was purchased from ProZyme, Inc. (San 
Leandro, CA). 
2. VPA-G Hydrolysis and Inhibition 
Either human liver subcellular fraction (cytosol, microsomes, mitochondria and lysosomes; 1 
mg/mL each) or recombinant human APEH (0.1 mg/mL) was preincubated in 50 mM Tris-HCl buffer (pH 
7.4) at 37°C.  Then, VPA-G (30 µM) was added to make a final volume of 0.05 – 0.1 mL and further 
incubation was performed at 37°C.  The reaction was stopped by adding the same volume of acetonitrile 
containing chlorzoxazone (0.5 – 5 µM, internal standard [IS]) as the reaction mixture and was centrifuged.  
An aliquot of 10 μL of each supernatant was injected into an LC/MS system.  Human liver lysosomes 
were also incubated in 50 mM sodium acetate buffer (pH 5).  In the inhibition studies, either PAPM, 
β-glucuronidase inhibitor (saccharolactone) or esterase inhibitor (DFP, eserine, BNPP, DTNB, EDTA, and 
PCMB) was added to the reaction mixture before preincubation.  In the β-glucuronidase study, bovine 
liver β-glucuronidase (200 Fishman unit/mL) was preincubated in 50 mM sodium acetate buffer (pH 5) 
and further incubation was performed after the addition of VPA-G. 
3. Measurement of VPA Concentration 
The concentrations of VPA in the incubation samples were analyzed using an LC/MS system 
consisting of an LC-10A (Shimadzu Corporation, Kyoto, Japan) coupled to an API3000 (Applied 
Biosystems/MDS SCIEX; Foster City, CA).  Chromatographic separation was achieved on a Capcell Pak 
C18 MG column (5 μm, 2.0 × 150 mm; Shiseido Co., Ltd., Tokyo, Japan) at a column temperature of 40°C.  
A mixture of acetonitrile/water (5/95, v/v) containing 5 mM ammonium acetate (mobile phase A) and 
acetonitrile/water (95/5, v/v) containing 5 mM ammonium acetate (mobile phase B) were used at a flow 
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rate of 0.3 mL/min.  The following gradient elution program was used: a linear increase of mobile phase 
B from 40% to 60% for 4 min followed by elution with 60% mobile phase B for 0.45 min.  The eluent 
from the column was introduced directly to the API3000 using the electrospray ionization interface in 
negative ion mode.  The ions of m/z 143 for VPA and m/z 168 for IS were monitored using the selected 
ion monitoring mode. For both VPA and IS, the declustering potential, curtain gas, ion spray voltage and 
ion source temperature were -31 V, 6 psi, -3,500 V and 550°C, respectively. 
4. LDH Activity in Human Liver Subcellular Fractions 
The LDH activity in human liver subcellular fractions was measured using an LDH assay kit 
(L-type Wako LDH, Wako Pure Chemicals) according to the manufacturer’s instructions. 
5. Purification of VPA-G Hydrolase from Human Liver Cytosol 
Human liver tissue was homogenized in a buffer (250 mM sucrose, 3 mM Tris and 1 mM EDTA 
[pH 7.4]) and the cytosol fraction was prepared by a conventional method.  Briefly, the cytosol was 
fractionated by ammonium sulfate and 20 to 70% (w/v) precipitate was obtained.  The precipitate was 
dissolved in 20 mM HEPES (pH 7) and dialyzed against the same buffer.  The dialysate was applied to a 
HiPrep 16/10 Q FF column (20 mL, GE Healthcare, Uppsala, Sweden) equilibrated with 20 mM HEPES 
(pH 7) and then a linear gradient of 0 to 0.5 M NaCl was applied to elute the enzyme.  The active 
fractions were combined and dialyzed against 10 mM of potassium phosphate buffer (pH 6.8) containing 
0.3 mM CaCl2.  The dialysate was applied to a Bio-Scale CHT2-I column (2 mL, Bio-Rad Laboratories, 
Hercules, CA) and then a linear gradient of 0 to 50% potassium phosphate buffer (500 mM, pH 6.8) 
containing 0.01 mM CaCl2 was applied to elute the enzyme.  After each active fraction was analyzed by 
SDS-PAGE, a 75-kDa protein band visualized by silver staining (EzStain Silver, ATTO Corporation, Tokyo, 
Japan) was excised and digested with trypsin within the gel.  The resulting peptides were extracted and 
sequenced by LC/MS/MS, which consisted of a DiNa nano-flow liquid chromatography system (KYA 
Tech, Tokyo, Japan) and an LTQ Orbitrap (Thermo Fisher Scientific, Waltham, MA).  The MS/MS 
spectra data were searched against a composite target/decoy IPI human database (version 3.72; 172784 
forward and reversed protein sequences) using Mascot 2.2 (Matrix Science, London, UK).  Parent mass 
and MS/MS tolerances were set at 50 ppm and 0.8 Da, respectively.  The author required strict enzyme 
specificity and allowed for up to two missed cleavage sites.  Carbamidomethylation of cysteine was set as 
the fix modification, and oxidation of methionine and N-acetylation of protein were searched as variable 
modifications.  The search results were filtered and summarized using in-house developed software.  In 
the software, the estimated false discovery rate of all peptide identifications was fixed at less than 1% by 
automatically filtering on mass error and peptide score of all forward and reverse peptide identifications. 
6. Preparation of Recombinant Human APEH with FLAG Tag 
The expression vector, pcDNA-NFLAG-GW, was prepared by Daiichi-Sankyo Co., Ltd.  
Ultimate ORF Clone (IOH3679, Matching nucleotide accession number: NM_001640.3, Invitrogen 
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Corporation, Carlsbad, CA), which has an open reading frame of human APEH, was recombined with 
pcDNA-NFLAG-GW by a Gateway LR reaction.  This vector was transfected into FreeStyle 293F cells 
(Invitrogen) using 293fectin (Invitrogen) according to the manufacturer’s instructions.  The transfected 
cells were cultured for 96 h and the harvest was centrifuged.  Recombinant APEH in the supernatant was 
applied to anti-FLAG M2 affinity gel (Sigma) and was eluted with FLAG peptide (Sigma).  The eluate 
was purified using the same procedure as described above. 
7. Antiserum and Immunodepletion 
A rabbit was immunized 8 times over a period of 3 months by subcutaneous injection of a mixture 
of recombinant APEH (100 μg) and oil adjuvant (Freund’s adjuvant complete [1st immunization only] or 
Freund’s adjuvant incomplete, Difco Laboratories Inc, Detroit, MI).  In 7 days after the final 
immunization, whole blood was collected and anti-APEH antiserum was obtained by centrifugation.  
Aliquots of 100 μL of Protein G Sepharose 4 Fast Flow beads (GE Healthcare) were washed with 500 μL 
of TNN.15 buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl and 0.1% NP-40) and centrifuged.  After 
discarding the supernatant, the precipitate was suspended in 400 μL of the same buffer.  A 50-μL aliquot 
of the antiserum was applied to the prepared beads and was gently mixed overnight at 4°C to retain the 
enzyme on the beads.  The antiserum binding beads were washed with 500 μL of TNN.15 buffer 3 times, 
followed by a wash with the same volume of TNN.1 (20 mM Tris-HCl [pH 7.4], 100 mM NaCl and 0.1% 
NP-40).  The beads were suspended with 500 μL of TNN.1.  Aliquots of 250 μL of the antiserum 
binding bead suspension were centrifuged and the supernatant was discarded.  To the beads, 40 μL of 
human liver cytosol and 360 μL of TNN.1 buffer were added and the suspension was mixed gently for 2 h 
at 4°C.  After centrifugation, the supernatant was treated with 250 μL of the bead suspension again.  The 
resulting supernatant obtained after centrifugation was used as APEH depleted cytosol and Western blot 
analysis was performed to check the depletion of APEH.  The various hydrolytic activity in the cytosol 
was also measured.  As a negative control, cytosol was also applied to beads treated with either 
preimmune serum or TNN.15 buffer. 
8. Western Blotting 
APEH depleted cytosol (10 µg) was separated by SDS-PAGE and was transferred 
electrophoretically onto a polyvinylidene difluoride membrane (Immun-Blot PVDF membrane, 0.2 µm, 
Bio-Rad).  APEH protein was detected with anti-APEH antiserum as a primary antibody and ECL 
anti-rabbit IgG horseradish peroxidase-linked, from donkey (GE Healthcare, 1:1,000,000 dilution) as a 
secondary antibody.  The immunoblots were visualized by chemiluminescence with an ECL Advance 
Western blotting detection kit (GE Healthcare). 
9. APEH Activity 
APEH activity in immunodepleted cytosol (0.1 mg/mL) was assayed as described below.  Each 
cytosol was incubated with AANA as a substrate in 100 mM Tris-HCl buffer (pH 7.4) at 37°C.  The 
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formation of p-nitroaniline was measured spectrophotometrically by monitoring the increase in absorbance 
at 405 nm. 
10. β-Glucuronidase Activity 
β-Glucuronidase activity in immunodepleted cytosol (0.1 mg/mL) was measured as described 
previously with a little modification [57].  Each cytosol was incubated with pNPG (5 mM) as a substrate 
in 100 mM sodium acetate buffer (pH 5) or 100 mM Tris-HCl buffer (pH 7.4) at 37°C.  The formation of 
p-nitrophenol was measured spectrophotometrically by monitoring the increase in absorbance at 405 nm. 
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Chapter 2, Section I 
1. Materials 
The materials stated above (Experimental Chapter 1.1) were used except as otherwise noted.  
Eserine, BNPP, and saccharolactone were purchased from Sigma-Aldrich Co. (St. Louis, MO).  MEPM 
was synthesized in Chemtech Labs, Inc. or purchased from Sumitomo Pharmaceutical Co. (Osaka, Japan).  
PCMB and p-nitroaniline were purchased from Tokyo Chemical Industries Co., Ltd. (Tokyo, Japan).  The 
other reagents were all commercially available and of guaranteed grade.  Pooled dog liver and renal 
cytosols were obtained from XenoTech, LLC (Lenexa, KS).  Individual dog liver and renal subcellular 
fractions were prepared as described in other literature.  Anti-human APEH antisera was obtained from a 
rabbit in Experimental Chapter 1.7. 
2. Animals 
Male Beagle dogs (n=3) were obtained from Nosan Corporation (Tokyo, Japan) and LSG 
Corporation (Tokyo, Japan).  The dogs ranged from 3 years to 7 years old and the body weight was 8.8 kg 
to 11.5 kg.  All experimental procedures were performed in accordance with the in-house guidelines of 
the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. 
3. Dog in vivo Study 
This was conducted as a crossover study with a washout period of more than one week.  Dogs 
subjected to common bile duct cannulation were intravenously coadministered 30 mg/kg of VPA and 
100 mg/kg of MEPM or physiological saline as the control.  Blood was collected at 0.25, 0.5, 1, 1.5, 2, 3, 
4 and 6 h after dosing and was centrifuged to obtain the plasma sample.  Urine and bile were collected for 
the periods of 0 to 1, 1 to 2, 2 to 4 and 4 to 6 h after dosing.  Plasma, urine, and bile samples were 
centrifuged after adding acetonitrile containing IS and the VPA and VPA-G concentrations in the 
supernatant were measured.  A liver biopsy sample was collected from one of the dogs at 6 h and 24 h 
after dosing under thiopental (inductive, 15 – 20 mg/kg) and isoflurane (continuous, 1.0 – 3.5%) anesthesia, 
maintaining warmth through a heatpad and applying anti-infectious treatments.  After a recovery period 
of two months, the dog was administered VPA and MEPM or saline again and the kidney biopsy sample 
was collected under the condition described above.  The S9 fraction of each sample was prepared as 
described above. 
4. Measurement of VPA and VPA-G Concentrations 
In vivo samples were analyzed using an LC-MS/MS system consisting of an LC-10ADvp 
(Shimadzu Corporation, Kyoto, Japan) coupled to an API4000 (Applied Biosystems/MDS SCIEX; Foster 
City, CA).  Chromatographic separation was achieved on a Capcell Pak C18 MGIII column (5 μm, 2.0 × 
50 mm; Shiseido Co., Ltd., Tokyo, Japan) at a column temperature of 50°C.  A mixture of water 
containing 1 mM ammonium acetate (mobile phase A) and acetonitrile/water (95/5, v/v) containing 20 mM 
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ammonium acetate (mobile phase B) were used at a flow rate of 0.4 ml/min.  The following gradient 
elution program was used: a linear increase of mobile phase B from 5% to 65% for 6 min followed by a 
linear increase of mobile phase B to 100% for 0.5 min.  The eluent from the column was introduced 
directly to the API4000 using the electrospray ionization interface in negative ion mode.  The transitions 
of m/z 319.0 to 112.9 for VPA-G, m/z 142.9 to 142.9 for VPA and m/z 168.0 to 131.9 for IS were 
monitored using the multiple reaction monitoring mode. 
5. Data Analysis 
PK parameters of VPA and VPA-G after administration of VPA to dogs were calculated using 
Phoenix WinNonlin (version 6.1, Pharsight Corporation) based on a noncompartmental method. 
6. Identification of a Dog VPA-G Hydrolase 
VPA-G hydrolase activity in dog liver and renal subcellular fraction and the inhibition 
Individual dog subcellular fractions (liver or renal cytosol, microsomes, mitochondria, lysosomes 
and S9; 1 mg/ml each) prepared from two dogs were preincubated in 50 mM Tris-HCl buffer (pH 7.4) at 
37°C.  Then, VPA-G (30 µM) was added to make a final volume of 0.1 ml and further incubation was 
performed at 37°C.  The reaction was stopped by adding the same volume of acetonitrile containing 
chlorzoxazone (0.5 µM, IS) as the reaction mixture and was centrifuged.  An aliquot of 10 μl of each 
supernatant was injected into an LC/MS system.  Dog liver and renal lysosomes were also incubated in 
50 mM sodium acetate buffer (pH 5).  In the inhibition studies, either carbapenems or esterase inhibitors 
were added to the reaction mixture before preincubation.  Pooled liver and renal cytosols were used in the 
inhibition study using esterase inhibitors.  The concentrations of VPA in the incubation samples were 
analyzed using a method described in Experimental Chapter 1. 3.   
 
Immunodepletion. 
Aliquots of 100 μl of Protein G Sepharose 4 Fast Flow beads (GE Healthcare) were washed with 
500 μl of TNN.15 buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl and 0.1% NP-40) and centrifuged.  
After discarding the supernatant, the precipitate was suspended in 400 μl of the same buffer.  A 50-μL 
aliquot of the antiserum was applied to the prepared beads and was gently mixed overnight at 4°C to retain 
the enzyme on the beads.  The antiserum binding beads were washed with 500 μl of TNN.15 buffer 3 
times, followed by a wash with the same volume of TNN.1 (20 mM Tris-HCl [pH 7.4], 100 mM NaCl and 
0.1% NP-40).  The beads were suspended with 500 μl of TNN.1.  Aliquots of 250 μl of the antiserum 
binding bead suspension were centrifuged and the supernatant was discarded.  To the beads, pooled dog 
liver or renal cytosol (2 – 4 mg/ml) in TNN.1 buffer was added and the suspension was mixed gently for 2 
h at 4°C.  After centrifugation, the supernatant was treated with 250 μl of the bead suspension again.  
The resulting supernatant obtained after centrifugation was used as the APEH depleted cytosol.  As a 
negative control, each fraction was also applied to the beads treated with either preimmune serum or 
TNN.15 buffer. 
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APEH and β-glucuronidase activity. 
APEH and β-glucuronidase activity in the immunodepleted cytosol (0.2 mg/ml) was measured as 
described in Experimental Chapter 1.9 and 1.10. 
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Chapter 2, Section II 
1. Materials 
The materials stated above (Experimental Chapter 1.1 and Chapter 2, Section I.1, respectively) 
were used except that VPA-G was purchased from Toronto Research Chemicals (Toronto, Canada). 
2. Animals 
Male chimeric TK-NOG mice with humanized liver prepared at the Central Institute for 
Experimental Animals (Kanagawa, Japan) and male control TK-NOG mice were obtained from In Vivo 
Science Inc. (Tokyo, Japan) (body weight 21 – 30 g).  In the chimeric mice, more than 70% of liver cells 
were estimated to have been replaced with human hepatocytes, as judged by measurements of human 
albumin concentrations in plasma performed by the supplier.  All experimental procedures were 
performed in accordance with the in-house guidelines of the Institutional Animal Care and Use Committee 
of Daiichi Sankyo Co., Ltd. 
3. Mouse in vivo Study 
The in vivo studies using the mice were performed 9 – 14 weeks after transplantation of human 
hepatocytes.  Three control mice and four chimeric mice were intravenously co-administered 30 mg/kg of 
VPA with 125 mg/kg of MEPM.  Three control mice and two chimeric mice were intravenously 
administered 30 mg/kg of VPA with physiological saline as the control.  Blood was collected at 0.25, 0.5, 
1, 1.5, 2, 3 and 4 h after dosing and was centrifuged to obtain the plasma sample.  After a washout period 
of two weeks, three control mice and three chimeric mice were co-administered of VPA with MEPM or 
saline again and urine was collected for the period of 0 to 24 h after dosing.  After drawing blood from 
the heart as much as possible, liver and kidney samples were obtained and were homogenized in a buffer 
(50 mM Tris-HCl, 0.2 mM EDTA, pH 7.4) of four-fold the volume of tissue weight.  The samples were 
centrifuged at 700 g for 10 min at 4ºC and the supernatant was used as the tissue homogenate.  Plasma 
and urine samples were centrifuged after adding acetonitrile containing IS and the plasma VPA, plasma 
VPA-G and urinary VPA-G concentrations in the supernatant were measured. 
4. Measurement of VPA and VPA-G Concentrations 
Plasma and urine samples were analyzed using an LC-MS/MS system consisting of an LC-20AD 
(Shimadzu Corporation, Kyoto, Japan) coupled to an API4000 (Applied Biosystems/MDS SCIEX; Foster 
City, CA).  Chromatographic separation was achieved on a Capcell Pak C18 MGIII column (5 μm, 2.0 × 
50 mm; Shiseido Co., Ltd., Tokyo, Japan) at a column temperature of 50°C.  A mixture of water 
containing 1 mM ammonium acetate (mobile phase A) and acetonitrile/water (95/5, v/v) containing 20 mM 
ammonium acetate (mobile phase B) were used at a flow rate of 0.4 ml/min.  The following gradient 
elution program was used: a linear increase of mobile phase B from 5% to 65% for 6 min followed by a 
linear increase of mobile phase B to 100% for 0.5 min.  The eluent from the column was introduced 
  47 
directly to the API4000 using the electrospray ionization interface in negative ion mode.  The transitions 
of m/z 319.0 to 112.9 for VPA-G in plasma, m/z 319.0 to 142.9 for VPA-G in urine, m/z 142.9 to 142.9 for 
VPA in plasma and m/z 168.0 to 131.9 for IS were monitored using the multiple reaction monitoring mode. 
5. Data Analysis 
PK parameters of VPA and VPA-G after administration of VPA to mice were calculated using 
Phoenix WinNonlin (version 6.3, Pharsight Corporation) based on a noncompartmental method. 
6. APEH Activity 
APEH activity in tissue homogenates was measured as described in Experimental Chapter 1.9 and 
1.10. 
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Chapter 3 
1. Materials 
The materials stated above (Experimental Chapter 1.1) were used except as otherwise noted.  
BSA and benzylpenicillin sodium salt were purchased from Sigma-Aldrich Co. (St. Louis, MO).  
14
C-MEPM was synthesized in Daiichi Pure Chemicals Co., Ltd. (Ibaraki, Japan).  The open β-lactam 
ring form of MEPM was synthesized at Sankyo Co., Ltd. (Tokyo, Japan).  Clavulanic acid potassium salt 
and ampicillin sodium salt were purchased from Wako Pure Chemicals (Osaka, Japan).  
6-Aminopenicillanic acid was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). The 
other reagents were all commercially available and of guaranteed grades.  Purified porcine liver APEH 
was obtained from Takara Bio Inc. (Shiga, Japan). 
2. Kinetic Parameters Determination 
Human liver cytosol (1 mg/mL) was preincubated in 50 mM Tris-HCl buffer (pH 7.4) at 37°C.  
Then, the preincubation mixture was incubated with VPA-G (1 – 200 µM) for 15 min at 37°C (the total 
reaction volume: 0.2 mL).  Likewise, purified porcine liver APEH (3.08 µg/mL) was incubated with 
VPA-G (1 – 30 µM) in 50 mM Tris-HCl buffer (pH 7.4) for 15 min at 37°C (the total reaction volume: 0.4 
mL).  The reaction was stopped by adding the same volume of acetonitrile containing chlorzoxazone 
(0.5 – 5 µM, IS) and was centrifuged.  VPA concentrations in the supernatant were measured by an 
LC/MS system consisting of an LC-10A chromatograph (Shimadzu Corporation, Kyoto, Japan) coupled to 
an API3000 (Applied Biosystems/MDS SCIEX; Foster City, CA) mass spectrometer.  Chromatographic 
separation was achieved on a Capcell Pak C18 MG column (5 μm, 2.0 × 150 mm; Shiseido Co., Ltd., 
Tokyo, Japan) at a column temperature of 40°C.  A mixture of acetonitrile/water (5/95, v/v) containing 5 
mM ammonium acetate (mobile phase A) and acetonitrile/water (95/5, v/v) containing 5 mM ammonium 
acetate (mobile phase B) were used at a flow rate of 0.3 mL/min.  The following gradient elution program 
was used: a linear increase of mobile phase B from 40% to 60% for 4 min followed by elution with 60% 
mobile phase B for 0.45 min.  The eluent from the column was introduced directly to the API3000 using 
the electrospray ionization interface in negative ion mode.  The ions of m/z 143 for VPA and m/z 168 for 
IS were monitored using the selected ion monitoring mode. For both VPA and IS, the declustering potential, 
curtain gas, ion spray voltage and ion source temperature were -31 V, 6 psi, -3,500 V and 550°C, 
respectively. 
3. Enzyme Inhibition 
IC50 determination. 
Various concentrations of PAPM, MEPM or the open ring form of MEPM (0 – 100 µM) were 
preincubated for 0 to 30 min with human liver cytosol (1 mg/mL) at 37°C.  Then the preincubation 
mixtures were incubated with VPA-G (3 µM, approximately equal to Km) and the production of VPA was 
determined. 
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Effect of other β-lactam antibiotics. 
Various concentrations of clavulanic acid, 6-aminopenicillanic acid, benzylpenicillin, ampicillin 
and MEPM (0 – 200 µM) were preincubated for 10 min with human liver cytosol (1 mg/mL) at 37°C.  
Then the preincubation mixtures were incubated with VPA-G (30 µM) and the production of VPA was 
determined. 
4. Effect of Dialysis 
Inhibition of VPA-G hydrolysis. 
Purified porcine liver APEH (0.5 nmol), MEPM (0.5 nmol) and Tris-HCl Buffer (50 mM, pH 7.4) 
were mixed (final volume 800 µL) and were incubated for 1 h at 37°C.  The reaction mixture was 
transferred into dialysis cassette (Slide-A-Lyzer Dialysis Cassette, 3.5K molecular weight cut-off, 
0.5 – 3.0 mL capacity, Pierce Biotechnology Inc., Rockford, IL) and was dialyzed twice against 300 mL of 
50 mM Tris-HCl at 4°C for 3 h and overnight, respectively.  APEH incubated without MEPM was also 
subjected to dialysis.  The VPA-G hydrolytic activity in the reaction mixture before and after dialysis was 
measured.  The inhibition ratio of activity was calculated by dividing the activity of APEH with 
incubation with MEPM by that with incubation without MEPM. 
 
Binding of MEPM to APEH. 
To examine the binding of MEPM to APEH, another dialysis experiment was performed using 
14
C-MEPM according to the same procedure as described above.  The radioactivity in the dialysate was 
divided by the initial radioactivity in the reaction mixture to calculate the binding ratio of 
14
C-MEPM to 
APEH.  To check the binding specificity of MEPM, the binding ratio to BSA was also examined. 
 
Effect of DFP on binding of MEPM to APEH. 
Porcine APEH was preincubated with DFP (0.5 nmol) for 30 min at 37°C and then was incubated 
with 
14
C-MEPM for 1 h.  The binding ratio was determined using the same procedure as described above.  
To check the non-specific effect of DFP, the binding ratio of MEPM to BSA after preincubation with DFP 
was examined. 
5. Data Analysis 
Km and Vmax for VPA-G hydrolysis in human liver cytosol were calculated using WinNonlin 
Professional (version 4.0.1, Pharsight Corporation) based on a pharmacodynamic compiled model (simple 
Emax model, model No. 101).  IC50 values of carbapenems were calculated using WinNonlin based on a 
pharmacodynamic compiled model (inhibitory effect sigmoid Emax model, model No. 107). 
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